Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
Date:3/19/2012

cStyle" type="disc">
  • Quality Financing.  Secured a financing in March 2011 yielding gross proceeds of $15 million with fundamental health care investors at market terms and without warrant coverage.
  • BEMA Buprenorphine - Chronic Pain.  Completed and announced results of the Phase 3, randomized, placebo-controlled clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic low back pain in a mixed population of opioid naive and experienced patients.  While the primary endpoint, overall pain intensity difference between BEMA Buprenorphine and placebo, was not achieved, a near statistically significant difference between BEMA Buprenorphine and placebo was seen in the opioid experienced group of patients in the trial (p=0.067), and further, when eliminating the group of patients that did not titrate beyond the starting dose, a statistically significant difference between BEMA Buprenorphine and placebo (p=0.025) was identified.  The knowledge gained in the study is being directly applied in partnership with Endo to the design of two additional Phase 3 trials anticipated to start in the third quarter of 2012.  BDSI believes such knowledge will enhance the probability of such trials meeting their primary endpoints.
  • BNX - Opioid Dependence.  Obtained positive results from two studies assessing the pharmacokinetics of BNX.  Results of the studies demonstrated the ability of the BEMA formulation to meet the key pharmacokinetic goal of delivering plasma concentrations of buprenorphine in the range needed to treat opioid dependence while minimizing the exposure to the abuse deterrent, naloxone.  Results of the studies were shared with FDA and an agreement was reached on the development program for BNX that is anticipated to result in a New Drug Application (NDA) for the treatment of opioid dependence in the first half of 2013.  Key data results from the pivotal phar
    '/>"/>

  • SOURCE BioDelivery Sciences International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
    7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
    8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
    9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
    10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
    11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... July 28, 2014  TNI BioTech, Inc. (OTCQB: ... focused on the development, marketing and distribution of ... definitive proxy materials with the Securities and Exchange ... of Shareholders to be held on Thursday, September ... The record date for determining those shareholders eligible ...
    (Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
    (Date:7/28/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 2014 financial results for the period ended June 30, 2014, ... will host a conference call and webcast that day at ... slide presentation relating to the call will be available via ... Call Details To access the live conference call via ...
    Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
    (Date:7/28/2014)... July 28, 2014 Ticket Down ... Roma tickets in Dallas, TX at the Cotton Bowl. ... in the USA and it is an eight team tourney. ... the world including teams from La Liga, Serie A, English ... will battle it out on the pitch include: Manchester ...
    (Date:7/28/2014)... Ticket Down is a dependable source ... FL at the Sun Life Stadium in early September. ... and Brazil has is one that has continues to go ... forming on a consistent basis. The rivalry between South ... the recent 2014 World Cup. To the delight of ...
    (Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... dementia and heart rhythm irregularities are more likely to get ... In fact, the study of more than 16,000 people ... more likely to get a pacemaker than those without the ... is why folks with dementia are so much more likely ...
    (Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
    (Date:7/28/2014)... July 28, 2014 UT Southwestern Medical Center ... and irreversibly interferes with the activity of a ... tumors. , The molecule, SML-8-73-1 (SML), interferes with ... oncogene homolog. The gene produces proteins called K-Ras ... can result in normal cells dividing uncontrollably and ...
    Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2
    ... Online Science Writers Webinar , NCI and ASCO will ... Wide Web that will explore key issues surrounding cancer ... experts from the United States, Africa, Asia and India ... Incidence, Survival and Mortality Trends , The State ...
    ... planning proton treatments makes it possible to precisely ... distributed inside the patient,s body, PALO ALTO, Calif., ... has received FDA 510(k) clearance for a new proton,scanning ... beams are used to target tumors and other abnormalities. ...
    ... Reliable, Quick Patient-Information Retrieval From Multiple ... Ill., Dec. 14 AT&T Inc. (NYSE: ... Associates, Ltd. (JOHA) has,awarded AT&T a three-year ... addition to other network solutions. Continuing its ...
    ... AMSTERDAM, December 14 Kiadis Pharma announced ... for regulatory,classification as a "cell based" medicinal product ... the European Medicines Agency (EMEA). Based upon,this regulatory ... a,next step Kiadis Pharma will file for orphan ...
    ... Online Help for Living Longer, ... Stronger, KIRKLAND, ... odds of needing long term care,increase. One solution is long term care insurance ... Financial Partners,(LTCFP), "is the insurance plus health habits to keep yourself on your ...
    ... generation begins to join the ranks of the retired so ... consumers, says a new study funded by the Economic and ... media creations, it seems that the caricatures of silver surfers ... of older people increasingly mirror those of the rest of ...
    Cached Medicine News:Health News:NCI/ASCO host science writers' seminar 2Health News:Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance 2Health News:Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance 3Health News:Local Joliet Physician Group Selects AT&T for Managed Online Data Solutions 2Health News:Local Joliet Physician Group Selects AT&T for Managed Online Data Solutions 3Health News:ATIR Classified as "Cell Based" Medicinal Product by the EMEA 2Health News:As More Americans Live to 100, Long Term Care Insurance Leader Gives Health Assist 2Health News:Retirees spending freely 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: